Yahoo Finance • 7 days ago
(RTTNews) - The biotech industry witnessed several key events this week, including major FDA approvals, acquisitions, pivotal clinical trial results and setbacks. • A series of FDA approvals were announced during the week, with GSK, Haloz... Full story
Yahoo Finance • 9 days ago
mezzotint / Shutterstock.com Quick Read Stocks took another beating on Wednesday amid concerns over the AI/Data Center trade. While inflation appears somewhat contained, any spike in the headline number today could send markets lower. Ho... Full story
Yahoo Finance • 12 days ago
European equities traded in the US as American depositary receipts kicked off the week higher late M PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 25 days ago
Below is Validea's guru fundamental report for ARGENX SE - ADR (ARGX). Of the 22 guru strategies we follow, ARGX rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology... Full story
Yahoo Finance • 25 days ago
European equities traded in the US as American depositary receipts were higher late Tuesday morning, PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 29 days ago
European equities traded in the US as American depositary receipts were trending higher late Friday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story
Yahoo Finance • last month
November 18, 2025–10:01 PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the results of it... Full story
Yahoo Finance • last month
This article first appeared on GuruFocus. Insightful Analysis of Frank Sands (Trades, Portfolio)' Third Quarter 2025 13F Filing Warning! GuruFocus has detected 7 Warning Signs with NVDA. Is NVDA fairly valued? Test your thesis with our f... Full story
Yahoo Finance • last month
ClearBridge Investments, an investment management company, released its “ClearBridge Mid Cap Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In an environment of shifting monetary policy, stabiliz... Full story
Yahoo Finance • 2 months ago
(RTTNews) - argenx SE (ARGX), Wednesday, announced that Health Canada has issued a Notice of Compliance authorizing VYVGART SC as a monotherapy for the treatment of adult patients with active chronic inflammatory demyelinating polyneuropat... Full story
Yahoo Finance • 2 months ago
Baron Funds, an investment management company, released its “Baron Health Care Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund rose 5.39% (Institutional Shares) in the quarter, compared to a... Full story
Yahoo Finance • 2 months ago
* argenx SE press release [https://seekingalpha.com/pr/20285593-argenx-reports-third-quarter-2025-financial-results-and-provides-business-update] (ARGX [https://seekingalpha.com/symbol/ARGX]): Q3 GAAP EPS of $5.18 beats by $0.83. * Rev... Full story
Yahoo Finance • 2 months ago
$1.13 billion in third quarter global product net sales On track to submit seronegative gMG sBLA by year-end and report ADAPT-OCULUS results in 1H26 – supporting pursuit of broadest MG label of any biologic Five registrational study read... Full story
Yahoo Finance • 2 months ago
VYVGART demonstrated clinically meaningful benefit across all AChR-Ab seronegative gMG subtypes in ADAPT SERON, supporting broad role of pathogenic IgGs in disease activityFinal ADAPT SC+ results show ~60% of VYVGART gMG patients achieved... Full story
Yahoo Finance • 2 months ago
Argenx SE (NASDAQ:ARGX) is one of the most profitable biotech stocks to buy. Citi analyst Samantha Semenkow maintained a Buy rating on Argenx SE (NASDAQ:ARGX) on October 23 and set a price target of $1,041. Argenx SE (NASDAQ:ARGX) also rec... Full story
Yahoo Finance • 2 months ago
Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. Global equity markets continued their strength in the third quarter, e... Full story
Yahoo Finance • 2 months ago
Pivotal ADAPT SERON results and interim ADAPT Jr data showcase VYVGART’s potential to treat broad set of myasthenia gravis patientsReal-world evidence and long-term data reinforce VYVGART’s sustained impact on patient outcomesMore than 40... Full story
Yahoo Finance • 3 months ago
European equities traded in the US as American depositary receipts were moving higher Wednesday morn PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 3 months ago
October 3, 2025 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Extraordinary Gen... Full story
Yahoo Finance • 3 months ago
The European market has shown resilience, with the pan-European STOXX Europe 600 Index rising by 1.03% amid expectations of a U.S. Federal Reserve interest rate cut, signaling optimism in the region's economic outlook despite some mixed si... Full story